Excellent points. If a high quality respected publication like Simply Wall Street recommends Clinuvel what else do you need?
maybe some revenue growth, some evidence of pipeline development, some promised board renewal.
so far the deeply strategic plan of hoping that competitors fall over is working well enough.
you say sws predicts earnings to rise by 26%. We will find out in the next week or 2. 10 years since EMA, 5 years since FDA and still less than 100 million in annual revenue with no competition
Ann: Becoming a substantial holder, page-11
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.18 |
Change
0.130(0.93%) |
Mkt cap ! $710.1M | |||
| Open | High | Low | Value | Volume |
| $14.07 | $14.30 | $14.06 | $749.7K | 52.90K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 161 | $14.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.30 | 1552 | 2 |
View Market Depth
| Last trade - 16.10pm 12/08/2024 (20 minute delay) ? |
| CUV (ASX) Chart |